참고문헌

1. Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax 1997; 52:416-21 https://doi.org/10.1136/thx.52.5.416
2. Bouros D, Schiza S, Tzanakis N. Chalkiadakis G, Drositis J, Siafakas N. Intrapleural urokinase versus normal saline In the treatment of complicated parapneumonic effusions and empyema: a randomized, double blind study. Am J Respir Crit Care Med 1999;159:37-42 https://doi.org/10.1164/ajrccm.159.1.9803094
3. Tuncozgur B, Ustunsoy H, Sivrikoz MC. Dikensoy O, Topal M, Sanli M, et al. Intrapleural urokinase in the management of parapneumonic empyema: a randomized controlled trial. Int J Clin Pract 2001;55:658-60
4. Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger CT. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med 2004;170:49-53 https://doi.org/10.1164/rccm.200312-1740OC
5. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, et al. U. K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005;352:865-74 https://doi.org/10.1056/NEJMoa042473
6. Tillett WS, Sherry S, Read CT. The use of streptokinase streptodornase in the treatment of postpneumonic empyema. J Thorac Surg 1951;21: 275-97
7. Cameron R, Davies H. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of parapneumonic effusions and empyema. Cochrane Database Syst Rev 2004;2:CD002312
8. Light RW, Nguyen T, Mulligan ME, Sasse SA. The in vitro efficacy of Varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculalted empyema. Lung 2000;178: 13-8 https://doi.org/10.1007/s004080000002
9. Simpson G, Roomes D, Heron M. Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus. Chest 2000;1l7: 1728-33 https://doi.org/10.1378/chest.117.6.1728
10. Simpson G, Roomes D, Reeves B. Successful treatment of empyema thoraces with human recombinant deoxyribonuclease. Thorax 2003;58:365-6 https://doi.org/10.1136/thorax.58.4.365
11. Ayed AK. Suction versus water seal after thoracoscopy for primary spontaneous pneumothorax: prospective randomized study. Ann Thorac Surg 2003;56:1593-6
12. Gossot D, Calette D, Stern JB, Debrosse D, Caliandro R, Girard P, et al. Results of thoracoscopic pleural abrasion for primary spontaneous pneumothorax, Surg Endosc 2004;18:466-71 https://doi.org/10.1007/s00464-003-9067-z
13. Lang-Lazdunski L, Chapuis O, Bonnet PM, Pons F, Jancovici R. Videothoracoscopic bleb excision and pleural abrasion for the treatment of primary spontaneous pneumothorax: long-term results. Ann Thorac Surg 2003;75:960-5 https://doi.org/10.1016/S0003-4975(02)04544-7
14. Margolis M, Gharagozloo F, Tempesta B, Trachiotis GD, Katz NM, Alexander EP. Video-assisted thoracic surgical treatment of initial spontaneous pneumothorax in young patients. Ann Thorac Surg 2003;76: 1661-4 https://doi.org/10.1016/S0003-4975(02)04816-6
15. Tschopp JM, Brutsche M, Frey JG. Treatment of complicated pneumothorax by simple talc pleurodesis under thoracoscopy and local anaesthesia Thorax 1997;52:329-32 https://doi.org/10.1136/thx.52.4.329
16. Cardillo G, Facciolo F, Regal M, Carbone L, Corzani F, Ricci A, et al. Recurrences following videothoracoscopic treatment of primary spontaneous pneumothorax: the role of redo-videothoracoscopy. Eur J Cardiothorac Surg 2001;19:396-9 https://doi.org/10.1016/S1010-7940(01)00611-X
17. Kennedy L, Sahn SA. Talc pleurodesis for the treatment of pneumothorax and pleural effusion. Chest 1994;106:1215-22 https://doi.org/10.1378/chest.106.4.1215
18. Chen JS, Hsu HH, Chen RJ, Kuo SW, Huang PM, Tsai PR, et al. Additional minocycline pleurodesis after thoracoscopic surgery for primary spontaneous pneumothorax. Am J Respir Crit Care Med 2006; 173:548-54 https://doi.org/10.1164/rccm.200509-1414OC
19. Chen JS, Hsu HH, Kuo SW, Tsai PR, Chen RJ, Lee JM, et al. Effects of additional minocycline pleurodesis after thoracoscopic procedures for primary spontaneous pneumothorax. Chest 2004;125:50-5 https://doi.org/10.1378/chest.125.1.50
20. Yim AP, Liu HP. Video assisted thoracoscopic management of primary spontaneous pneumothorax. Surg Laparosc Endosc 1997;7:236-40 https://doi.org/10.1097/00019509-199706000-00012
21. Sahn SA. Management of malignant pleural effusions. Monaldi Arch Chest Dis 2001;56:394-9
22. Heffner JE, Sahn SA, Brown LK. Multilevel likelihood ratios for identifying exudative pleural effusions. Chest 2002;121:1916-20 https://doi.org/10.1378/chest.121.6.1916
23. Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988;138:184-234 https://doi.org/10.1164/ajrccm/138.1.184
24. Cheng D, Lee YC, Rogers JT. Vascular endothelial growth factor level correlates with transforming growth factor-beta isoform levels in pleural effustions. Chest 2000;118:1747-53 https://doi.org/10.1378/chest.118.6.1747
25. Anderson CB, Philpott GW, Ferguson TB. The treatment of malignant pleural effusions. Cancer 1974;33:916-22 https://doi.org/10.1002/1097-0142(197404)33:4<916::AID-CNCR2820330405>3.0.CO;2-U
26. Grath G, Catzemeier U, Haussingen K, Heckmayr M, Magnussen H, Neuhauss R, et al. Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann Oncol 1991;2:213-5 https://doi.org/10.1093/annonc/2.suppl_2.213
27. Gene O, Petrou M, Ladas G, Goldstraw P. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg 2000;18:143-6 https://doi.org/10.1016/S1010-7940(00)00422-X
28. Martini N, Bains MS, Beattie EJ Jr. Indications for pleurectomy in malignant effusion. Cancer 1975;35: 734-8 https://doi.org/10.1002/1097-0142(197503)35:3<734::AID-CNCR2820350328>3.0.CO;2-N
29. Aelony Y. Dry talc pleurodesis via chest tube. Chest 2003;123:308 https://doi.org/10.1378/chest.123.1.308
30. Aelony Y, King PR, Boutin C. Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH. Chest 1998;113: 1007-12 https://doi.org/10.1378/chest.113.4.1007
31. Crnjac A. The significance of thoracoscopic mechanical pleurodesis for the treatment of malignant pleural effusion. Wien Klin Wochenschr 2004;116:S28-S32
32. Ong KC, Indumathi V, Raghuram J, Ong YY. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology 2000;5:99-103 https://doi.org/10.1046/j.1440-1843.2000.00235.x
33. Chella A, Ribechini A, Dini P, Adamo C, Mussi A, Angeletti CA Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis. Minerva Chir 1994;49:1077-82
34. Cheng D, Chan YM, Ng TY, Cheung AN, Ngan HY, Wong LC. Mitomycin chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to gynecological cancer, Acta Obstet Gynecol Scand 1999;78:443-6 https://doi.org/10.1080/j.1600-0412.1999.780518.x
35. Martinez-Moragon E, Aparicio J, Rogado MC, Sanchis J, Sanchis F, Gil-Suay V. Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J 1997;10:2380-3 https://doi.org/10.1183/09031936.97.10102383
36. Putnam Jr JB, Light RW, Rodriguez RM, Ponn R, Olak J, Pollak JS, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999;86:1992-9 https://doi.org/10.1002/(SICI)1097-0142(19991115)86:10<1992::AID-CNCR16>3.0.CO;2-M
37. Tanaka N, Takazawa K, Fujita M, Tamura S, Odani Y, Hirayama Y, et al. Adult case of isolated noncompaction of left ventricular myocardium revealed at hospitalization for tuberculous pleuritis. J Cardiol 1999;33:169-74
38. Rosso R, Rimoldi R, Salvati F, De Palma M, Cinquegrana A, Nicolo G, et al. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988;45:253-6 https://doi.org/10.1159/000226571
39. Lissoni P, Mandala M, Curigliano G, Ferretti G, Moro C, Ardizzoia A, et al. Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. Oncology 2001; 60:308-12 https://doi.org/10.1159/000058525
40. Senyigit A, Bayram H, babayigit C, Topcu F, Balci AE, Batici O. Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases. Respiration 2000;67:623-9 https://doi.org/10.1159/000056291
41. Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European organisation for research and treatment of cancer lung cancer group and the national cancer institute of Canada. J Clin Oncol 2005;23:6881-9 https://doi.org/10.1200/JCO.20005.14.589
42. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44 https://doi.org/10.1200/JCO.2003.11.136
43. Castagneto B, Zai S, Dongiovanni V, Manzin E, Clerico M, Botta M. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Proc Am Soc Clin Oncol 2003;22:656[abstract 2637]
44. Portalone L, Antilli A, Nunziati F, Crispino C, Demarinis F, Friggeri L, et al. Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma. Tumori 2005;91:15-8
45. Ceresoli G, Zucali P, Favaretto A, Grossi F, Bidoli P, Del Conte G, et al. A phase II study of pemetrexed and carboplatin as first-line chemotherapy in patients with malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 2005:7172 [abstract]
46. Fennell DA, C Steele JP, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2006;47:277-81 https://doi.org/10.1016/j.lungcan.2004.08.005
47. Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002;8:294-301 https://doi.org/10.1097/00063198-200207000-00009
48. Roberts WG, Palade GE, Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108:2369-79
49. Hamed EA, EI-Noweihi AM, Mohamed AZ, Mahmoud A. Vasoactive mediators (VEGF and TNF-$\alpha$) in patients with malignant and tuberculous pleural effusions. Respirology 2004;9:81-6 https://doi.org/10.1111/j.1440-1843.2003.00529.x
50. Sack D, Hoffmann M, Zhao XJ, Chan KS, Hui DS, Gosse H, et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 2005;25:600-4 https://doi.org/10.1183/09031936.05.00037004
51. Yano S. Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000; 157:1893-903 https://doi.org/10.1016/S0002-9440(10)64828-6
52. Yano S, Herbst RS, Shinobara H, Knighton B, Bucana CD, Killion JJ, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000;6: 957-65
53. Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V, Cirino G, et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 2005;314:738-44 https://doi.org/10.1124/jpet.105.086553